1. Autophagy Metabolic Enzyme/Protease Apoptosis
  2. p62 E1/E2/E3 Enzyme Apoptosis
  3. P62-RNF168 agonist-1

P62-RNF168 agonist-1 (compound 5a) is a low cytotoxicity P62-RNF168 agonist that enhances the interaction between P62 and RNF168. P62-RNF168 agonist-1 induces a reduction in H2A ubiquitination mediated by RNF168 and impairs homologous recombination-mediated DNA repair. P62-RNF168 agonist-1 also inhibits the growth of xenograft tumors in mice in a dose-dependent manner.

For research use only. We do not sell to patients.

P62-RNF168 agonist-1 Chemical Structure

P62-RNF168 agonist-1 Chemical Structure

CAS No. : 2765180-17-2

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 333 In-stock
Solution
10 mM * 1 mL in DMSO USD 333 In-stock
Solid
5 mg USD 385 In-stock
10 mg USD 578 In-stock
25 mg USD 1098 In-stock
50 mg USD 1538 In-stock
100 mg USD 2153 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

P62-RNF168 agonist-1 (compound 5a) is a low cytotoxicity P62-RNF168 agonist that enhances the interaction between P62 and RNF168. P62-RNF168 agonist-1 induces a reduction in H2A ubiquitination mediated by RNF168 and impairs homologous recombination-mediated DNA repair. P62-RNF168 agonist-1 also inhibits the growth of xenograft tumors in mice in a dose-dependent manner[1].

Cellular Effect
Cell Line Type Value Description References
A-375 IC50
1.93 μM
Compound: 5a
Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
[PMID: 36331508]
A549 IC50
1.18 μM
Compound: 5a
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
[PMID: 36331508]
HCT-116 IC50
0.36 μM
Compound: 5a
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
[PMID: 36331508]
HeLa IC50
2.48 μM
Compound: 5a
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
[PMID: 36331508]
HepG2 IC50
19.61 μM
Compound: 5a
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
[PMID: 36331508]
MCF-10A IC50
6.98 μM
Compound: 5a
Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
[PMID: 36331508]
MCF7 IC50
2.79 μM
Compound: 5a
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
[PMID: 36331508]
MDA-MB-231 IC50
1.17 μM
Compound: 5a
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
[PMID: 36331508]
MGC-803 IC50
1.88 μM
Compound: 5a
Cytotoxicity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
[PMID: 36331508]
U2OS IC50
3.64 μM
Compound: 5a
Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
[PMID: 36331508]
In Vitro

P62-RNF168 agonist-1 (20 μM, 72 h) has an IC50 of 0.36 μM for the cancer cell line HCT116 and an IC50 of 1.18 μM for A549. It shows cytotoxicity against cancer cells A357, HeLa, HepG2, MCF-7, MDA-MB-231, MGC-803, and H2OS, but does not induce cell apoptosis and has lower toxicity towards normal cells MCF-10A[1].
P62-RNF168 agonist-1 (1-5 μM; 24 h) affects the HR (homologous recombination)-mediated DSB repair in HCT-116 cells, contributing to its antitumor activity[1].
P62-RNF168 agonist-1 enhances the interaction between P62 and RNF168 in HCT-116 cells, with a Kd of 20.97 μM[1].
P62-RNF168 agonist-1 inhibits the catalytic activity of RNF168 and the E3 ligase activity of RNF168 in HCT-116 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: A549, HCT-116, A375, HeLa, HepG2, MCF-7, MDA-MB-231, MGC-803, U2OS and MCF-10A cells
Concentration: 0-20 µM
Incubation Time: 72 h
Result: Inhibited A549, HCT-116, A375, HeLa, HepG2, MCF-7, MDA-MB-231, MGC-803, U2OS and MCF-10A cells, with IC50 values of 1.18, 0.36, 1.93, 2.48, 19.61, 2.79, 1.17, 1.88, 3.64 and 6.98, respectively.

Cell Cycle Analysis[1]

Cell Line: HCT-116 cells
Concentration: 1, 2, 5 µM
Incubation Time: 24 h
Result: Induced a G2/M arrest but no significant accumulation of sub-G1 phase.
Compromised both HR(homologous recombination)- and NHEJ (non-homologous end joining)- mediated DSB repair in a dose-dependent manner, but HR was the more severely impacted process.

Western Blot Analysis[1]

Cell Line: HCT-116
Concentration: 10 µM
Incubation Time: Over night
Result: Had the expression of RNF168 and GST-RNF168 ,increased the level of P62 in the endogenous RNF-168 immune complex.

Apoptosis Analysis[1]

Cell Line: HCT-116
Concentration: 5, 10 µM
Incubation Time: 24 h
Result: Made apoptosis less obvious.
In Vivo

P62-RNF168 agonist-1 (12.5-100 mg/kg, i.p., single dose) has an MTD of 50 mg/kg in BALB/c mice, while in female nude mice, the MTD is 12.5 mg/kg[1].
P62-RNF168 agonist-1 (5-10 mg/kg, i.p., single every 3 days for 22 days) promotes tumor apoptosis and inhibits tumor growth in mice[1].
1.19 Pharmacokinetic Parameters of Antitumor agent-81 in Female BALB/c nude mice[1].

Dose T1/2 (h) Cmax (ng/mL) AUC0-t (h?ng/mL) CL ((mL/h)/kg)
IP (5 mg/kg) 16.17 26.10 215.69 19647.83
IP (10 mg/kg) 31.00 39.87 408.18 16554.30
IP (20 mg/kg) 22.10 52.23 1003.58 14669.81

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female BALB/c nude mice (xenograft tumor model)[1].
Dosage: 5, 10 mg/kg
Administration: Intraperitoneal injection; single every 3 days for 22 days
Result: Suppressed tumor growth by promoting apoptosis in xenografted tumorigenesis.
Animal Model: Female BALB/c nude mice[1].
Dosage: 5, 10, 20 mg/kg
Administration: Intraperitoneal injection; single
Result: Exhibited plasma concentration peaked 1 h after administration.
Showed a relatively high maximum concentration (Cmax= 52.23 ng/mL) and exposure (AUC0-t= 1003.58 h•ng/mL) at a dose of 20 mg/kg.
Animal Model: BALB/c mice, Female nude mice[1]
Dosage: 25, 50, 75, 100 mg/kg, single dose; 12.5, 25, 50 mg/kg, single dose
Administration: Intraperitoneal injection
Result: Showed in the 100 mg/kg dosage group of BALB/c mice, out of 8 animals, 3 males and 3 females died on the 7th day, and the remaining animals experienced diarrhea. In the 75 mg/kg dosage group, 1 out of 8 animals (1 male) had diarrhea on the 7th day. There were no deaths or diarrhea observed in the ≤50 mg/kg dosage group.
Showed in the female nude mice, both the 25 and 50 mg/kg dosage groups experienced deaths or diarrhea, while the 12.5 mg/kg dosage group had no deaths or diarrhea.
Molecular Weight

393.40

Formula

C19H19N7O3

CAS No.
Appearance

Solid

Color

Off-white to light yellow

SMILES

NC1=C2C(C=CC(C3=CN(C4=CC(OC)=C(C(OC)=C4)OC)N=N3)=C2)=NC(N)=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : ≥ 60 mg/mL (152.52 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5419 mL 12.7097 mL 25.4194 mL
5 mM 0.5084 mL 2.5419 mL 5.0839 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.4 mg/mL (6.10 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.4 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (24.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.4 mg/mL (6.10 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.4 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (24.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5419 mL 12.7097 mL 25.4194 mL 63.5486 mL
5 mM 0.5084 mL 2.5419 mL 5.0839 mL 12.7097 mL
10 mM 0.2542 mL 1.2710 mL 2.5419 mL 6.3549 mL
15 mM 0.1695 mL 0.8473 mL 1.6946 mL 4.2366 mL
20 mM 0.1271 mL 0.6355 mL 1.2710 mL 3.1774 mL
25 mM 0.1017 mL 0.5084 mL 1.0168 mL 2.5419 mL
30 mM 0.0847 mL 0.4237 mL 0.8473 mL 2.1183 mL
40 mM 0.0635 mL 0.3177 mL 0.6355 mL 1.5887 mL
50 mM 0.0508 mL 0.2542 mL 0.5084 mL 1.2710 mL
60 mM 0.0424 mL 0.2118 mL 0.4237 mL 1.0591 mL
80 mM 0.0318 mL 0.1589 mL 0.3177 mL 0.7944 mL
100 mM 0.0254 mL 0.1271 mL 0.2542 mL 0.6355 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
P62-RNF168 agonist-1
Cat. No.:
HY-151799
Quantity:
MCE Japan Authorized Agent: